1. Overview
  2. All Stocks
  3. Cybin Inc. Common Stock

Cybin (HELP.US) Price Target 2026/2027: 220% Upside – Rating and Stock Analysis

11,07
5,13%
Analysis framework by , founder of TradeDesk · Data: EODHD, official filings (SEC) · Updated
Price history for Cybin (HELP.US) – stock price at 11.07 $, August 2026
Cybin stock price – price development 2026. Updated Aug 6, 2026.
Share this analysis:

Cybin Price Target 2026: Analysts See 218% Upside

The average price target for Cybin is $35.21. This price target represents the analysts' view of the stock price over the next 12 months. The stock may be undervalued, because the price target is higher than the current price. The stock is 218,07% below the target, which can point to potential returns within the next 12 months if the analysts' view proves right. Also consider the stock's valuation ratios such as P/E, P/S and P/B, plus the technical analysis further down the page, for the full picture.

Is Cybin overvalued or undervalued?

Cybin is currently undervalued with a gap of 218.1% relative to the price target.


The current price is $11.07, which places Cybin in the undervalued category. The stock is considered undervalued when the price is below $31.69, and overvalued when the price exceeds $38.73.


The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For Cybin, the fair value range lies between $31.69 and $38.73.


See the full price target analysis for Cybin →

↑ Back to navigation

About Cybin – Bioteknologi

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada. Read more about the company

Key Figures for Cybin

$ 575M Market cap
- Revenue
Bioteknologi Industry
- P/E
16,436.36 P/S
2.09 P/B
USA Listed on exchange
helus.com Website
Sundhed Sector

What kind of stock is Cybin?

Momentum stock

Cybin is classified as a momentum stock with a momentum score in the top 1% of all stocks. The price has risen 0.0% over the long term.

Score Overview for Cybin

💰 Value Score 15/100 (Very Low)
⭐ Quality Score 15/100 (Very Low)
🚀 Momentum Score 99/100 (Very High)
📊 Total Score 43/100

⚠️ 1 red flag identified 1 critical

Our analysis has identified 1 potential risk factor in Cybin that investors should be aware of.

🚨 Negative return on equity: ROE is -74.6% – the company is generating a negative return for shareholders.

📈 Valuation

The P/S ratio is 16,436.4 (high — the market pays a premium for the revenue). The P/B ratio is 2.1.

🏦 Financial Health

The Piotroski score is 4 out of 9 — average financial health. Altman Z2 is 8.86 (healthy balance sheet — low risk). The debt-to-equity ratio (D/E) is 9.0% — low debt, a solid balance sheet.

↑ Back to navigation

When Does Cybin Report Earnings – Next Date: 8/12/2026

The next earnings report from Cybin is scheduled for August 12, 2026. This report covers the second quarter (Q2), which ended on June 30, 2026.



↑ Back to navigation

Technical Analysis of Cybin 2026 – Signal: Strong Buy

Overall Technical Signal: Strong Buy

Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated August 6, 2026.

Technical analysis of Cybin (HELP.US) – RSI 81, MACD positive (bullish), daily candlestick chart August 2026
Cybin technical analysis – candlestick chart with RSI and MACD. Updated Aug 6, 2026.

Trend Analysis of Cybin Inc. Common Stock

Cybin Inc. Common Stock is in a short-term uptrend. The price of $10.53 is 37.6% above the 20-day average ($7.66). Medium term, the picture is positive: the price is 74.0% above the 50-day average ($6.05). Long term, the stock is 71.7% above the 200-day average ($6.13), which confirms a long-term uptrend.

Death Cross: The 50-day average (6.05) is below the 200-day average (6.13), which is a classic bearish signal for Cybin Inc. Common Stock.

Is Cybin Inc. Common Stock overbought or oversold?

Cybin Inc. Common Stock has an RSI of 81.4, which places the stock in overbought territory (above 70). Even though the stock is overbought, the broader trend is positive. A short-term pullback is possible, but the trend still supports the price.

MACD Analysis for Cybin Inc. Common Stock

Daily MACD: MACD is positive (0.849), which means the short-term trend is bullish (the 12-day EMA is above the 26-day EMA). MACD is above the signal line (0.671) by 0.178, which confirms rising momentum in the uptrend.

Weekly MACD: MACD5 is positive (0.344), which indicates a broader bullish long-term trend. MACD5 is above the signal line (-0.178) by 0.522, which confirms rising long-term momentum.

Overall MACD assessment: Both the daily and weekly MACD are positive and above their signal lines. Trend and momentum confirm each other across time horizons – the strongest bullish signal.

Risk Profile for Cybin Inc. Common Stock

Cybin Inc. Common Stock has an annual standard deviation of 82.9%, which classifies the stock as extreme risk. Only risk-tolerant investors should consider this stock, because the price swings can be very large.

Overall Technical Conclusion for Cybin Inc. Common Stock

Trend: Positive. The price trades above SMA50 and SMA200.

MACD trend (zero line): Daily bullish (0.849). Weekly bullish (0.344).

MACD momentum (signal): Daily rising. Weekly rising.

RSI: 81.4 – overbought.

Technical signal: Strong Buy

The price is in an uptrend (above SMA50/SMA200) and MACD is positive on both a daily and weekly basis. Trend and MACD trend confirm each other – the strongest technical buy signal.

↑ Back to navigation

Frequently Asked Questions About Cybin stock in 2026

Should you buy Cybin stock now?
Yes, the technical signal for Cybin is currently BUY. Cybin trades at $11.07 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.849 with rising momentum (signal: 0.671); RSI is at 81.4 (overbought), suggesting the price may have risen too quickly; the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $35.21 points to 218.1% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Cybin stock?
The average analyst price target for Cybin is $35.21. The current price is $11.07, which gives an upside of 218.1%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $31.69 and $38.73.
Is Cybin a dividend stock?
No, Cybin does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Cybin stock?
Cybin is rated as a stock with extreme risk. the annual standard deviation is 82.9%, which classifies the stock as extreme risk. In addition, an RSI of 81.4 signals overbought (elevated risk of a pullback).
Is Cybin overvalued?
No, Cybin is considered undervalued based on the analyst price target (218.1% upside). Cybin has the following valuation ratios: a P/S ratio of 16,436.4, a P/B ratio of 2.1. The analyst price target suggests that the stock is undervalued by 218.1%.
Is Cybin overbought?
Yes, Cybin is overbought with an RSI of 81.4 (above 70). The technical indicators show: RSI is at 81.4 (above the 70 mark), which signals the price is overbought and may have risen too quickly. In addition, the price is 44.6% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Cybin earnings report?
Cybin reports its next earnings on August 12, 2026. The stock currently trades at $11.07. The RSI is at 81.4, so the report can reinforce the current technical trend.
Is Cybin shorted?
There is currently no registered short interest for Cybin, or the data is not available.
Are insiders buying Cybin stock?
There is currently no registered insider trading for Cybin.
Is Cybin a good stock?
Based on our total score, Cybin is rated as a mediocre stock with a total score of 43 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 15/100, Quality: 15/100, Momentum: 99/100. In addition: analysts see 218.1% upside to the price target; technical signal: Strong Buy. Whether Cybin is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Cybin stock?
The outlook for Cybin based on current data: the average analyst price target is $35.21 (+218.1%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on 8/12/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Cybin stock rising?
Cybin is rising right now. The technical indicators show: the price is 44.6% above the 20-day average; MACD is positive with rising momentum (bullish signal). For the latest context, see our technical analysis, insider section and news overview above.
How high can Cybin go?
The average analyst price target for Cybin is $35.21, which corresponds to a potential gain of 218.1% from the current price of $11.07. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Cybin fall?
We lack enough history to give a specific floor for Cybin. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Cybin do?
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to trea... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Cybin as an investment.
Did Cybin raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Cybin. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Cybin making money or losing money?
We have no current profitability data for Cybin. See the latest report in the earnings history above.
Can Cybin go bankrupt?
The bankruptcy risk of Cybin is rated as low. Altman Z2 (a model for assessing financial distress) is 8.86 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 4 — which is average. Debt relative to equity is 9% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Cybin have a lot of debt?
No, Cybin has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 9%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
↑ Back to navigation

Explore More